CN106103479B - 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 - Google Patents

识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 Download PDF

Info

Publication number
CN106103479B
CN106103479B CN201580011755.4A CN201580011755A CN106103479B CN 106103479 B CN106103479 B CN 106103479B CN 201580011755 A CN201580011755 A CN 201580011755A CN 106103479 B CN106103479 B CN 106103479B
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
ccr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580011755.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106103479A (zh
Inventor
阿迪·莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of CN106103479A publication Critical patent/CN106103479A/zh
Application granted granted Critical
Publication of CN106103479B publication Critical patent/CN106103479B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CN201580011755.4A 2014-03-04 2015-03-04 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 Active CN106103479B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947852P 2014-03-04 2014-03-04
US61/947,852 2014-03-04
PCT/IL2015/050234 WO2015132790A2 (en) 2014-03-04 2015-03-04 Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines

Publications (2)

Publication Number Publication Date
CN106103479A CN106103479A (zh) 2016-11-09
CN106103479B true CN106103479B (zh) 2019-12-24

Family

ID=52815066

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580011755.4A Active CN106103479B (zh) 2014-03-04 2015-03-04 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体

Country Status (11)

Country Link
US (2) US10246508B2 (https=)
EP (2) EP3114139B1 (https=)
JP (1) JP6553075B2 (https=)
CN (1) CN106103479B (https=)
BR (1) BR112016020366B1 (https=)
DK (1) DK3114139T3 (https=)
ES (1) ES2926700T3 (https=)
IL (1) IL247219B (https=)
PT (1) PT3114139T (https=)
RU (1) RU2705255C2 (https=)
WO (1) WO2015132790A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183028A1 (en) * 2016-04-18 2017-10-26 Chemomab Ltd. Eotaxin-2 inhibitors in the treatment of fibromyalgia
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
ES3052981T3 (en) 2017-01-24 2026-01-16 Kyowa Kirin Co Ltd Therapeutic or prophylactic agent for treating radiation damage
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
IL251024A0 (en) * 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US10945904B2 (en) 2019-03-08 2021-03-16 Auris Health, Inc. Tilt mechanisms for medical systems and applications
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230192836A1 (en) 2020-04-20 2023-06-22 Chemomab Ltd. Ccl24 inhibitors in the treatment of covid-19
CA3172627A1 (en) 2020-04-22 2021-10-28 Adi Mor Method of treatment using anti-ccl24 antibody
EP4143227A2 (en) * 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027880A2 (en) * 1998-11-11 2000-05-18 Fondazione Centro San Raffaele Del Monte Tabor Rantes-derived peptides with anti-hiv activity
CN102307899A (zh) * 2009-01-28 2012-01-04 特拉维夫医学中心医学研究,基础设施及健康服务基金 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
CN102782148A (zh) * 2009-08-28 2012-11-14 Vlst公司 与多种cc趋化因子结合的抗因子抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999119B2 (en) * 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027880A2 (en) * 1998-11-11 2000-05-18 Fondazione Centro San Raffaele Del Monte Tabor Rantes-derived peptides with anti-hiv activity
CN102307899A (zh) * 2009-01-28 2012-01-04 特拉维夫医学中心医学研究,基础设施及健康服务基金 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
CN102782148A (zh) * 2009-08-28 2012-11-14 Vlst公司 与多种cc趋化因子结合的抗因子抗体

Also Published As

Publication number Publication date
JP2017508461A (ja) 2017-03-30
EP3114139B1 (en) 2022-06-15
EP4155317A1 (en) 2023-03-29
PT3114139T (pt) 2022-09-13
BR112016020366B1 (pt) 2024-01-02
RU2016136639A (ru) 2018-04-05
US10479830B2 (en) 2019-11-19
IL247219A0 (en) 2016-09-29
RU2705255C2 (ru) 2019-11-06
US20160368979A1 (en) 2016-12-22
WO2015132790A3 (en) 2015-11-05
EP3114139A2 (en) 2017-01-11
US20190153088A1 (en) 2019-05-23
ES2926700T3 (es) 2022-10-27
CN106103479A (zh) 2016-11-09
WO2015132790A2 (en) 2015-09-11
DK3114139T3 (da) 2022-09-12
JP6553075B2 (ja) 2019-08-07
IL247219B (en) 2021-09-30
RU2016136639A3 (https=) 2018-05-04
US10246508B2 (en) 2019-04-02
BR112016020366A2 (pt) 2018-06-05

Similar Documents

Publication Publication Date Title
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
JP2023537422A (ja) Ｉｌ－１１の抗体及びその使用
TWI908724B (zh) TrkA的抗體及其應用
WO2024017331A1 (zh) 一种抗肾上腺髓质素非中和抗体、其制备方法及应用
TW201333034A (zh) 新穎抗人類ｃｔｇｆ抗體
US12018074B2 (en) Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
CN117003877A (zh) Prdx1 IgG中和抗体及其制备方法和在制备急性器官损伤或脓毒症药物中的应用
CA3227057A1 (en) Use of alpha-enolase antagonist in treating fibrotic diseases
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
US20230192836A1 (en) Ccl24 inhibitors in the treatment of covid-19
CN116635422A (zh) 抗cd38抗体及其用途
JP7565607B2 (ja) 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
WO2025152915A1 (zh) 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用
CN121773333A (zh) 基于尿uc5b-9检测的通过局部补体抑制对补体介导的疾病进行的靶向治疗
CN117843784A (zh) 抗人cd73抗体或其抗原结合片段及其应用
CN121319179A (zh) 一种抗il-31ra抗体及其制备方法与用途
CN117866092A (zh) 抗人cd73抗体或其抗原结合片段及其应用
WO2017183028A1 (en) Eotaxin-2 inhibitors in the treatment of fibromyalgia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant